No Data
No Data
Express News | Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Earnings Preview: ARQT to Report Financial Results Post-market on May 06
TD Cowen Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $20
Arcutis Biotherapeutics: Buy Rating Affirmed Amid Positive Long-Term Outlook and Strategic Growth Potential
Here's Why Arcutis Biotherapeutics (NASDAQ:ARQT) Can Manage Its Debt Despite Losing Money
Arcutis to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025